The U.S. Food and Drug Administration approved a new 7.2 mg weekly injection dose of Wegovy (semaglutide) on March 19, tripling the previous maximum dose of 2.4 mg. The approval was based on the STEP UP phase 3b randomized controlled trial conducted in 2025 by manufacturer Novo Nordisk. The trial reported an average weight loss of 18.7 percent, with one in three participants achieving at least 25 percent weight reduction. Sample size was not disclosed in the secondary reporting and the trial carries a conflict of interest as it was sponsored by the drug developer. The FDA noted the safety profile is consistent with known semaglutide effects, primarily gastrointestinal issues including nausea, diarrhea, constipation, vomiting, and abdominal pain. Higher doses were associated with increased reports of altered skin sensations that generally resolve. Recent observational data also suggest a potential elevated risk of ischemic optic neuropathy (eye stroke), particularly in males, possibly linked to faster weight loss. Independent expert Dr. Meghan Garcia-Webb, triple board-certified in internal medicine, lifestyle medicine, and obesity medicine, expressed cautious optimism, noting slightly lower serious adverse events in the 7.2 mg group in the trial but called for real-world monitoring. Patients should discuss risks, especially pre-existing eye conditions, with healthcare providers. Long-term use is typically required to sustain benefits. This coverage is derived from secondary news reporting rather than the primary peer-reviewed trial publication. Source: https://www.healthline.com/health-news/fda-approves-higher-dose-wegovy-shot-weight-loss